JP2019535754A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535754A5 JP2019535754A5 JP2019527426A JP2019527426A JP2019535754A5 JP 2019535754 A5 JP2019535754 A5 JP 2019535754A5 JP 2019527426 A JP2019527426 A JP 2019527426A JP 2019527426 A JP2019527426 A JP 2019527426A JP 2019535754 A5 JP2019535754 A5 JP 2019535754A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound according
- compound
- pharmaceutically acceptable
- equation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(CCC(*(*)*)C(*(*)C(CCCC*(*)C(CCCc1ccc(*)cc1)=O)O)=O)=O Chemical compound CC(CCC(*(*)*)C(*(*)C(CCCC*(*)C(CCCc1ccc(*)cc1)=O)O)=O)=O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425810P | 2016-11-23 | 2016-11-23 | |
| US62/425,810 | 2016-11-23 | ||
| PCT/US2017/063182 WO2018098390A1 (en) | 2016-11-23 | 2017-11-24 | Albumin-binding psma inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535754A JP2019535754A (ja) | 2019-12-12 |
| JP2019535754A5 true JP2019535754A5 (enExample) | 2021-01-07 |
| JP7167021B2 JP7167021B2 (ja) | 2022-11-08 |
Family
ID=60812130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019527426A Active JP7167021B2 (ja) | 2016-11-23 | 2017-11-24 | アルブミン結合ｐｓｍａ阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11147889B2 (enExample) |
| EP (1) | EP3544960A1 (enExample) |
| JP (1) | JP7167021B2 (enExample) |
| CN (1) | CN109982998A (enExample) |
| BR (1) | BR112019010206A2 (enExample) |
| CA (1) | CA3043619A1 (enExample) |
| MX (1) | MX2019005742A (enExample) |
| WO (1) | WO2018098390A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7282792B2 (ja) * | 2017-10-22 | 2023-05-29 | プロビンシャル・ヘルス・サービシーズ・オーソリティ | 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物 |
| US20210276971A1 (en) * | 2018-06-20 | 2021-09-09 | The Research Foundation For The State University Of New York | Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same |
| JP2022507477A (ja) * | 2018-11-14 | 2022-01-18 | ノリア・セラピューティクス・インコーポレイテッド | チオアミド含有構成物 |
| WO2020108753A1 (en) * | 2018-11-28 | 2020-06-04 | ITM Isotopen Technologien München AG | Novel tumor antigen binding agents and uses thereof |
| WO2020210909A1 (en) | 2019-04-17 | 2020-10-22 | Provincial Health Services Authority | Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer |
| CA3144094A1 (en) | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| CN115210240A (zh) | 2020-03-04 | 2022-10-18 | 日本医事物理股份有限公司 | 化合物及放射性标记化合物 |
| CA3178858A1 (en) * | 2020-05-06 | 2021-11-11 | Cornell University | Copper-containing theragnostic compounds and methods of use |
| US20240131206A1 (en) * | 2020-12-04 | 2024-04-25 | The Regents Of The University Of California | Peptide receptor radionuclide therapy |
| US20240018110A1 (en) * | 2020-12-16 | 2024-01-18 | The University Of British Columbia | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| CN114685599A (zh) * | 2020-12-30 | 2022-07-01 | 南京江原安迪科正电子研究发展有限公司 | 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途 |
| EP4303213A4 (en) * | 2021-03-04 | 2024-09-18 | Nihon Medi-Physics Co., Ltd. | Compound and radioactive labeling compound |
| US20250186627A1 (en) * | 2022-03-04 | 2025-06-12 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| WO2024126687A1 (en) * | 2022-12-16 | 2024-06-20 | Silence Therapeutics Gmbh | Nucleic acids conjugated to an albumin binding moiety |
| WO2024169037A1 (zh) * | 2023-02-16 | 2024-08-22 | 无锡诺宇医药科技有限公司 | Psma靶向放射性药物及其合成和应用 |
| CN116217505B (zh) * | 2023-03-17 | 2024-10-01 | 南京医科大学 | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0621973D0 (en) * | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| EP3222617B1 (en) | 2009-03-19 | 2022-07-06 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
| EP2739316B1 (en) | 2011-08-05 | 2019-04-10 | Molecular Insight Pharmaceuticals, Inc. | Radiolabeled prostate specific membrane antigen inhibitors |
| US10011632B2 (en) * | 2011-08-22 | 2018-07-03 | Siemens Medical Solutions Usa, Inc. | PSMA imaging agents |
| CN106061981A (zh) * | 2013-11-06 | 2016-10-26 | 索尔斯蒂斯生物有限公司 | 具有二硫化物基团的多核苷酸构建体 |
| JP6464166B2 (ja) * | 2013-11-14 | 2019-02-06 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | 陽電子放出断層撮影用の化合物 |
| PL3183236T3 (pl) * | 2014-08-24 | 2022-07-18 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften | Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma |
| PL3356385T3 (pl) | 2015-09-30 | 2021-06-28 | Deutsches Krebsforschungszentrum | Tagowane 18F inhibitory antygenu błonowego specyficznego dla gruczołu krokowego (PSMA) i ich zastosowanie jako środków do obrazowania w nowotworze gruczołu krokowego |
| SI3925952T1 (sl) * | 2016-03-22 | 2024-03-29 | The Johns Hopkins University | Za prostato specifična, na membranski antigen usmerjena visoko afinitetna sredstva za endoradioterapijo raka prostate |
| US10179117B2 (en) * | 2016-06-23 | 2019-01-15 | Cornell University | Double targeted constructs to affect tumor kill |
| DE102016122273B4 (de) | 2016-11-18 | 2018-06-21 | Abx Advanced Biochemical Compounds Gmbh | Präkursoren für die Radiofluorierung |
-
2017
- 2017-11-24 CA CA3043619A patent/CA3043619A1/en active Pending
- 2017-11-24 JP JP2019527426A patent/JP7167021B2/ja active Active
- 2017-11-24 EP EP17821755.0A patent/EP3544960A1/en not_active Withdrawn
- 2017-11-24 MX MX2019005742A patent/MX2019005742A/es unknown
- 2017-11-24 BR BR112019010206A patent/BR112019010206A2/pt not_active Application Discontinuation
- 2017-11-24 CN CN201780071927.6A patent/CN109982998A/zh active Pending
- 2017-11-24 US US16/349,756 patent/US11147889B2/en active Active
- 2017-11-24 WO PCT/US2017/063182 patent/WO2018098390A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535754A5 (enExample) | ||
| US8435489B2 (en) | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma | |
| EP1389209B1 (en) | Folate mimetics and folate-receptor binding conjugates thereof | |
| JP5421114B2 (ja) | 低酸素症選択性の弱塩基性２−ニトロイミダゾール送達薬剤およびその使用方法 | |
| US11147889B2 (en) | Albumin-binding PSMA inhibitors | |
| US11541133B2 (en) | Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes | |
| JP2018058847A5 (enExample) | ||
| JP2014510729A5 (enExample) | ||
| JP2018199694A5 (enExample) | ||
| RU2011146362A (ru) | Набор для предварительного таргетинга, способ и средства, используемые в нем | |
| JP2010523599A5 (enExample) | ||
| WO2008124651A3 (en) | Nitro-imidazole hypoxia imaging agents | |
| JP2005534626A5 (enExample) | ||
| JP2010511704A5 (enExample) | ||
| CA3030907A1 (en) | Chelated psma inhibitors | |
| DE602004017290D1 (de) | Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel | |
| JP2015528814A5 (enExample) | ||
| CA2722858C (en) | Substrate based pet imaging agents | |
| JP2018502150A5 (enExample) | ||
| JP2009538894A5 (enExample) | ||
| Das et al. | 177Lu-DOTMP: a viable agent for palliative radiotherapy of painful bone metastasis | |
| JP2013504590A5 (enExample) | ||
| Welch et al. | Production of non-standard PET radionuclides and the application of radiopharmaceuticals labeled with these nuclides | |
| JP2018511648A5 (enExample) | ||
| US20090028791A1 (en) | Dichloroacetate Analogs as Imaging Agents |